Significance of endocrine therapy for unresected primary breast cancer

Kanako Kurata, Masaya Kai, Makoto Kubo, Hitomi Mori, Mai Yamada, Yuji Nakafusa, Masafumi Nakamura

Research output: Contribution to journalArticlepeer-review


At present, surgery is still the recommended principal treatment for breast cancer. However, there are conditions in which surgery is not suitable, for example in elderly or high-risk patients and those who do not wish to undergo the procedure. This study presents a case series of 8 patients with unresected breast cancer who were administered hormonal therapy as an optional treatment. Patients included in the study were diagnosed with Stage I - ID breast cancer from 2012 to 2015 at our institution. The patients were administered hormonal therapy for an average duration of 20.1 months. Complete responses were seen in 4 patients, while 1 and 3 patients were noted to have a partial response and stable disease, respectively. No disease progression was seen in any patients during the study period. Endocrine therapy may be an effective and safe option for patients with unresected breast cancer.

Original languageEnglish
Pages (from-to)1645-1647
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Issue number11
Publication statusPublished - Nov 2018

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Significance of endocrine therapy for unresected primary breast cancer'. Together they form a unique fingerprint.

Cite this